you, and Thank afternoon, Linnell, everyone. good
begin Let's business our update. with
this that we accelerate mentioned Xoft our the strategic the focus business synergies provide and As options growth. on accessibility for exploring are more call, previous of and technology its could to
continue While therapy. targeted this operate we worldwide the these treat options, patients with to continue explore we business to and customers
to lower Xoft was future. slowed concerns, are $X.X retain support distributors we our versus address as the XX% QX while stack coming internal And redeployed than about some business' and for in and to cautious customers sales have resources we've $X.XX these revenue better budget support Sales sales. million. million To at services,
the at Xoft to of Compelling with researchers journal a Xoft that longest-term skin peer-reviewed of patients Xoft report to in of published was evidence of I grow. to-date, supporting last skin Brachytherapy. recurrence-free cancer and remaining eBx of X.X Contemporary the XX.X% for body quarter years. treatment safe non-melanoma pleased In is am new confirmed median research continues a follow-up study effective the
Xoft options the puts fewer study for cancer confident time. We that safety, them We'll comfort surgery that the impact evidence the effects who updates to reoccurrence to but technology for and with in and providers skin further adds at potential on This has global with convenience body point appropriate more remain eBx clinical Mohs terms care rates, a lives of and side the in positively efficacy its on provide strategic the on par of and the patients of Xoft patients. scale.
to potential, and prior business, solely be Turning while the call, AI. and mentioned our we core have around as to great our believe market and detection both lines competencies need side and our the detection our detection focus of therapy on strategy business on of earnings opportunity
which Force before saw But published news. moment just Services a risk screening mammography women this Preventive to begin draft at to Task speak U.S. you go of the guidelines, earlier week's of into XX. we QX new this recommend sure take many results, I'm announcement They've want mammography week. to from age I average
women demand With for XX, to to the technology services. U.S. XX offer ages potential XX women ability recommendations benefit for to the increased the million meet the between these of more our improve in these and providers'
miss present standard cancers of gold for about cancer can at breast screening. However, breast although mammography still XX% time of the screening, it is the
risk. the the Mammography if long-term, in the a also and she's short women's a or not cancer of determine of specify how do know guidelines risk woman new developing cannot would average
of and comprised mammography. risk, the maximizes suite density AI breast Our effectiveness of detection,
accuracy and up to competitors proven leading compared times and to performance for to is Our clinically two detection clinical improve solution radiologists. delivers the efficiency
was solution to detection might recent XX% shown have undetected. up a cancers study, to otherwise catch our that gone more In
has been to meets it up density FDA, the only personalized to than but outlined risk solution more the worldwide not solution our accurate traditional recently X.X enhance used needs times results. patient models. is And by long risk Our care and
portfolio more is the commercially ever. AI U.S. clinically breast Force the to breast guidelines, more solution that women detect practice technology in XXX-degree proven daily And clear clinicians leading-edge recent risk cancers, of Our only it's Task developing Services Preventive relevant available cancer. evaluate than and our identify density is to with high assist at
our to back QX updates. So
note, we leaders year, Senior U.S. business. poised Bill QX with this our Sales. team vision as Commercial we to grow of brought our of on President, strengthened seasoned First In and Keyes our execute leadership strategic Vice
As with to enterprise healthcare the leader record team teams, building Bill technology sales than expertise driving a via brings years and track consistent of leading experience, more in growth a sales seasoned Software-as-a-Service. in XX and
and served as We of Avadhanula new worked past years with Vasu also recently welcomed team to leader recently G. development, can innovation as analytics with outstanding at an he that Vasu Officer. Susan XX and Technology Vice President, the Komen. Health Transformation attest experience. our the Digital is several business Chief Vasu over years most product Product I've technology and
direct-to-patient customer a patient-powered of well our and roadmap. to has successful look role at to Komen's launch perspective research registry. Health the in as Komen, status experience. share including G. pleased programs him to Vasu In Cloud, first the and and I'm forward as the a record our ideas Software-as-a-Service incorporating turning unique patient team instrumental welcome quo future Komen the and breast platform Vasu procurers, that cancer enhance his development into engagement track into of Susan his products new services, of disrupt success was the last
growing with healthcare partnerships. Strong than and building we as Komen. Chief tackling our as strengthen in Marketing organizations, to leader more at new recently initiatives Susan President leadership marketing G. and a as welcomed challenging our seasoned Michelle strategic Continuing Officer Operations Vice experience excels also technology, Michelle serving years recently XX of team, most Strategy is of strategically who and developing
advance in that engagement the implementation strategies Komen's and leadership, year-over-year, increased experienced revenues brand business in broaden growth. and Michelle's She equity to cancer. unique awareness, to be significant bolster new go-to-market her breast stakeholder save welcome resulting the our of pleased that expertise of I'm revenue to instrumental team its in her skills to health will drive success. lives Under set improvements and brand and from confident specializes mission
full Lonnqvist as recent pleased iCAD's and has acumen Officer. report to our strong Directors Eric and Financial that Vice to our I'm demonstrated Additionally, of Chief commitment President of we've a search for Eric completed financial position his the appointed CFO new Analysis. Board most a as Planning as in excellence Financial time
three you business leading and strong and the that time, company. the during and for the leadership Eric's technology operations a industries, through will more leader medical instrumental and on a financial through hear combined iCAD changes. been and Eric with Eric than been style, has years, experience in in strong has over of this be later device and acumen XX leadership and financial with more stable of years accounting will Eric finance market call.
payer strategic The these partnerships addition advocacy of patient initiatives such accelerate companies company's pharmaceutical key with groups, seasoned in organizations. and plans, executives new as will the
help the team, With people AI have vision changes right breast screening to of us confident right the we're right achieve leadership these time pervasive technology. to we roles our and offering in most important at the our personalized the
that company, breast to the exciting And these work patients. Congress transformations compelling our a and benefits while of clinicians and women's share offers Meeting, evidence at real-world portfolio new detection see again commonly research iCAD's continues to validate In the positive breast has cancer as a and we were lives. Radiology physicians ECR, AI March, referred European on to clinical their impact we as experience suite pleased AI to on
of presentation detection Women's Health solution Boca Christine E. Medical our AI Raton by & of meeting, among the at findings XX% found Hospital a Kathy breast In the Schilling, study Wellness Institute research Lynn increasing increased profound cancer nine imaging the recalls. without the the detection Regional dedicated session rate presented radiologists Dr. rate that from the Director at
studies media Schilling. note. will syndicated more Dr. was the iCAD ProFound upcoming and you research technology and Both experience, of this invite sharing improvement Schilling this nationally featuring CBS be demonstrating took with the and join so May This We our segments XX. practices Dr. for the offers study all compelling along to unique Insights, on us our and clinical Webinar covered webinar. case best ProFound in Impact significant about benefits Fox our
and more assessments. clinical for was ProFound supporting of was AI to evidence also long-term lifestyle last of study Tyrer-Cuzick for New commonly mammography be used risk X, than the accurate Oncology Clinical And Version accurate ProFound XD both risk ProFound found AI risk published to more our the model. note, quarter. risk is short-term AI risk Journal in a findings, According
current breast cancer. known patient's the about Physicians estimated as women have no by history. of history such examining family breast are family who XX% breast of But risk cancer have factors traditionally risk cancers
identified cancers solution X.X% accurately Our XX% personalized. breast only care risk compared been for With has patient risk iCAD's risk never solution, Tyrer-Cuzick. to as of more high
mammographies and empowering to a they healthcare can cancer overall ultimately tailor saving about risk, finding most woman's breast more lives. specific and to importantly, which screening cost By with the effectiveness, radiologists information sooner, cancer system maximize leads reducing
and dense in aged for all over first breast prevalent most XX% is dense of which national cancer FDA women factors. a healthcare significant the nearly the reporting implementation advancement one as women breasts, of and Also strongest breast the in quarter, standard, have the a risk announced of XX
breast notifications dense the as assessment as themselves. are However, only effective
even wide the As AI and lead ICAD's lead This clinicians and in facility can own assessment assessment for care. increase additional in to be may variation and disagree patient agreement, confusing imaging visual radiologists breast patients, year-to-year. their suite to empowers unnecessary studies show with way costs. breast
breast they And new density equipped with facilities technology standards regulations. provide to to assessments, solutions our to in we work accurate are demand well line more this using as expect assessment and federal customers bring our care density
Vienna. was Turning of well-attended just over world. now as marked very We mentioned, to distributors with from by our customers ECR the our I in a the many QX all potential operations meeting of U.S., connected outside
a compelling Schilling Dr. to and evening and XXX more case testimonies audience leaders of from demonstrating event who AI, radiologists. talks featuring our Dr. We of imaging special also than breast studies power renowned an clinical the shared hosted Grawingholt, technology including Axel in Kathy
with was partner workshop to in team radiologists. GE our a pleased Also, for
German-speaking screening their Switzerland. screening in the process. ProFound will one On review the expanding AI that This and be in the side, AI ProFound first detection sales will program will risk largest iCAD use into be regions of
grow With the visibility territories, iCAD's on our distribution scale. to a global of continues expansion
our on becoming are to Our before the to offering this bringing uptake is brief in purchasing financial where more opportunities, want demand for model partners lastly, Europe, preferred regional move in significant provide quickly we and a in also significant a update, we're update transition. business model. seeing you and the our larger subscription And I
on noted of by million million changes, XXXX. our on implemented to and call, strategic As by annualized cash $X.X continued burn our putting and achieve goal our cost $X.X base, reducing including measures annualized cost profitability reduction align us track to several $X.X last we million, exiting $X.X streamline to million expenses to
our noted more we on annual our recurring S-ARR We up call, subscription make last material our metric revenue. and or when consistent also a earnings revisit revenue, deals will subscription of portion
pleased closed report we're lines, subscription nine these in Along deals we QX. that to
predictable total create While to our the across only of revenue, it on model a subscription-based as does for stream, impact more revenue long-term profitable term. is we're able the we revenue small short-term and contract it believe to license recognize move good portion a spread because a builds a future
call mentioned recap, process direct range that to today to to assessments personalized rigorous also other patients a through evaluate elective like last growth thoughtful risk earlier access include and pursuing assessment solutions, strategies and of a and the a To offerings digital AI going screenings payer predictive and covered. these new we're get going risk opportunities. reimbursement I on red with care GPT-powered to scoring platform, and
and help and large and on cancers employers provide aid initiatives other tackling to supporting modalities. health to patient AI get our screening campus, women's expanding health on advocacy with mobile the women programs breast all address to need the utilizing with front platform cloud-based they disparities Partnering AI-powered healthcare access to of organizations services lines
competitive In a on to the customer on focus milestones We of and strategy stability, later and summary, diversifies and moves year. you our strategy update we're defensible forward continuing smooth company look making to rapidly transform that preserving concentration. the our metrics bold to cash revenue this out and with a long-term building this stream
to over call financials. of the turn review now QX, I'll detailed for XXXX a Eric our
